Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis.
Nadia QuignotHeng JiangIndraraj Umesh DoobareeJan LehmannOla GhatnekarPublished in: ClinicoEconomics and outcomes research : CEOR (2023)
The overall cost burden of this BCG-treated cohort of 1049 patients is high (€38 million whereof 4.1 million are indirect costs) over a mean follow-up of 3.9 years; economic burden is especially substantial for patients who fail BCG treatment and those who progress.